Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CTR20262442 Human fibrinogen (Sinopharm Group Shanghai Blood Products) Deficiency Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262442 clinical trial report covering Human fibrinogen (Sinopharm Group Shanghai Blood Products), Phase 3, endpoints, sponsor, geography, readout timing
Latest Hotspot
8 min read
NCT07678684 ATRA liposome Glioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07678684 clinical trial report covering ATRA liposome, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600127469 Ivonescimab Locally Advanced Malignant Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
ChiCTR2600127469 clinical trial report covering Ivonescimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07678229 Anlotinib Dihydrochloride Extranodal NK-T-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07678229 clinical trial report covering Anlotinib Dihydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07679360 Trastuzumab Rezetecan Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07679360 clinical trial report covering Trastuzumab Rezetecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07678957 Trastuzumab Brengitecan HR-positive/HER2-low Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07678957 clinical trial report covering Trastuzumab Brengitecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600127436 VG081821AC Cognitive Dysfunction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
ChiCTR2600127436 clinical trial report covering VG081821AC, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07678827 Viloxazine Hydrochloride Attention Deficit Disorder With Hyperactivity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07678827 clinical trial report covering Viloxazine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07677579 Retifanlimab Rectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07677579 clinical trial report covering Retifanlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07677891 PG-102(ProGen) Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07677891 clinical trial report covering PG-102(ProGen), Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07679269 Trastuzumab PIK3CA-related overgrowth syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07679269 clinical trial report covering Trastuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262512 Apatinib Mesylate Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262512 clinical trial report covering Apatinib Mesylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.